Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIMUS 006 - A Phase II Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06498518 is registered in ClinicalTrials.gov with Karen Carty as lead sponsor.

NCT NCT06498518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06498518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIMUS 006 - A Phase II Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Karen Carty
Phase
Phase 2
Overall status
Withdrawn
Start date
June 17, 2024
Completion date
May 23, 2025
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms pancreatic